Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02913131 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
A Phase 1 study, sponsored by Rahul Aggarwal.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02913131 is a Phase 1 study that was terminated before completion, run by Rahul Aggarwal. The registered enrollment target is 23 participants.
The verdict
NCT02913131, a Phase 1 study, was terminated before completion, sponsored by Rahul Aggarwal.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a single center prospective imaging study investigating the utility of hyperpolarized C-13 pyruvate as a Biomarker of PI3K/mTOR pathway inhibition in patients with advanced solid tumor malignancies. The current protocol will serve as a companion imaging biomarker study paired with therapeutic trials of PI3K/mTOR pathway inhibitors (e.g. CUDC-907, BYL719), as well as a stand-alone protocol for patients treated with standard-of-care therapies inhibiting the PI3K/mTOR signaling pathway (eg. everolimus).
Interventions
- DEVICE MRI
- DRUG Pyruvate (13C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-10-20 |
| Est. Completion | 2021-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02913131
The ClinicalTrials.gov registry entry for NCT02913131 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rahul Aggarwal, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI is the first listed.
NCT02913131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02913131 about?
NCT02913131 is a clinical study titled "Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies". This is a single center prospective imaging study investigating the utility of hyperpolarized C-13 pyruvate as a Biomarker of PI3K/mTOR pathway inhibition in patients with advanced solid tumor malignancies. The current protocol will serve as a companion imaging biomarker study paired with therapeuti...
What is the current status of trial NCT02913131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-10-20. Estimated completion is 2021-04-05.
What interventions are being tested in trial NCT02913131?
The interventions under investigation include: MRI (DEVICE), Pyruvate (13C) (DRUG).
Who is sponsoring clinical trial NCT02913131?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.